{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:13:53Z","timestamp":1783548833463,"version":"3.55.0"},"reference-count":58,"publisher":"Academy of Medicine, Singapore","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Acad Med Singap"],"published-print":{"date-parts":[[2023,12,28]]},"abstract":"<jats:p>Introduction: Two decades after the Rotterdam 2003 consensus workshop, there have been considerable advances in elucidating the pathophysiology and epidemiology of polycystic ovary syndrome (PCOS). This has prompted the re-examination of the features that characterise this common condition. Current definitions have led to great heterogeneity in the prevalence of PCOS and have contributed to inconsistent treatment protocols and assessment of therapeutic outcomes. Diagnosis is further complicated by the lack of universal agreement on threshold cut-offs for ovarian dysfunction and ethnic differences in hirsutism; both of which are key features in the definitions that are commonly used currently. These challenges often result in dissatisfaction with medical care among PCOS patients and their physicians.\n\nMethod: Our factor analysis mathematically identified anti-Mullerian hormone (AMH), associated polycystic ovarian morphology (PCOM) and serum testosterone as the only significant cluster associated with menstrual cycle length variability.\n\nResults and Conclusion: As such, we propose a simplified criteria wherein the presence of at least 2 of the 3 features below would be sufficient to define PCOS: (1) chronic oligo-ovulation or anovulation as indicated by oligomenorrhea (cycle lengths &gt;35 days) or amenorrhea; (2) PCOM: raised AMH \u226537.0 pmol\/L instead of transvaginal ultrasound assessment of ovaries; and (3) Androgen excess or raised serum androgens above the laboratory reference for women. Further studies are required to examine whether the proposed criteria would reduce diagnostic confusion and improve care and outcomes, especially among patients of East Asian ethnicities.<\/jats:p>","DOI":"10.47102\/annals-acadmedsg.202369","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T08:03:36Z","timestamp":1703750616000},"page":"669-678","source":"Crossref","is-referenced-by-count":5,"title":["Polycystic ovary syndrome v.2023: Simplified diagnostic criteria for an East Asian phenotype"],"prefix":"10.47102","volume":"52","author":[{"given":"Eu-Leong","family":"Yong","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Shan","family":"Teoh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26165","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Yong EL. Polycystic Ovarian Syndrome \u2013 Issue 30.8. Best Pract Res Clin Obstet Gynaecol 2016;37:1-4.","DOI":"10.1016\/j.bpobgyn.2016.09.001"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Chiaffarino F, Cipriani S, Dalmartello M, et al. Prevalence of polycystic ovary syndrome in European countries and USA: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2022;279:159-70.","DOI":"10.1016\/j.ejogrb.2022.10.020"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Liu J, Wu Q, Hao Y, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod 2021;36:1108-19.","DOI":"10.1093\/humrep\/deaa371"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol 2022; 10:668-80.","DOI":"10.1016\/s2213-8587(22)00163-2"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219-31.","DOI":"10.1038\/nrendo.2010.217"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Riestenberg C, Jagasia A, Markovic D, Buyalos RP, et al. Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences. J Clin Endocrinol Metab 2022;107:575-85.","DOI":"10.1210\/clinem\/dgab613"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hampton T. NIH panel: Name change, new priorities advised for polycystic ovary syndrome. JAMA 2013;309:863.","DOI":"10.1001\/jama.2013.1236"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Kubota T. Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan. Reprod Med Biol 2013;12:71-7.","DOI":"10.1007\/s12522-013-0145-1"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Yanagihara R, Matsuzaki T, Aoki H, et al. Compatible cut-off values for luteinizing hormone and the luteinizing hormone\/ follicle-stimulating hormone ratio in diagnostic criteria of the Japan Society of Obstetrics and Gynecology for polycystic ovary syndrome. J Obstet Gynaecol Res 2023;49:253-64.","DOI":"10.1111\/jog.15423"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.","DOI":"10.1016\/S0002-9378(15)30642-6"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR and Haseltine F (Eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific;1992.","DOI":"10.1007\/978-1-4613-8483-0_8"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Nestler JE. Sex hormone-binding globulin: a marker for hyperinsulinemia and\/or insulin resistance? J Clin Endocrinol Metab 1993;76:273-4.","DOI":"10.1210\/jcem.76.2.8432767"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.","DOI":"10.1093\/humrep\/deh098"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Lujan ME, Jarrett BY, Brooks ED, et al. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013;28:1361-8.","DOI":"10.1093\/humrep\/det062"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Gibson-Helm M, Dokras A, Karro H, et al. Knowledge and Practices Regarding Polycystic Ovary Syndrome among Physicians in Europe, North America, and Internationally: An Online Questionnaire-Based Study. Semin Reprod Med 2018;36:19-27.","DOI":"10.1055\/s-0038-1667155"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Teoh WS, Ramu D, Indran IR, et al. Diagnosis and management of polycystic ovary syndrome: Perspectives of clinicians in Singapore. Ann Acad Med Singap 2022;51:204-12.","DOI":"10.47102\/annals-acadmedsg.2021474"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Indran IR, Huang Z, Khin LW, et al. Simplified 4-item criteria for polycystic ovary syndrome: A bridge too far? Clin Endocrinol (Oxf) 2018;89:202-11.","DOI":"10.1111\/cen.13755"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88.","DOI":"10.1016\/j.fertnstert.2008.06.035"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018;110:364-79.","DOI":"10.1093\/humrep\/dey363"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Neubronner SA, Indran IR, Chan YH, et al. Effect of body mass index (BMI) on phenotypic features of polycystic ovary syndrome (PCOS) in Singapore women: a prospective cross-sectional study. BMC Womens Health 2021;21:135.","DOI":"10.1186\/s12905-021-01277-6"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Tay CT, Garrad R, Mousa A, et al. Polycystic ovary syndrome (PCOS): international collaboration to translate evidence and guide future research. J Endocrinol 2023;257:e220232.","DOI":"10.1530\/joe-22-0232"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Dapas M, Lin FTJ, Nadkarni GN, et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis. PLoS Med 2020;17:e1003132.","DOI":"10.1371\/journal.pmed.1003132"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Chang S, Dunaif A. Diagnosis of Polycystic Ovary Syndrome: Which Criteria to Use and When? Endocrinol Metab Clin North Am 2021;50:11-23.","DOI":"10.1016\/j.ecl.2020.10.002"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Al Wattar BH, Fisher M, Bevington L, et al. Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study. J Clin Endocrinol Metab 2021; 106:2436-46.","DOI":"10.1210\/clinem\/dgab232"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Yan D, Yan-Fang W, Shi-Yang Z, et al. Is polycystic ovary syndrome appropriately diagnosed by obstetricians and gynaecologists across China: a nationwide survey. J Ovarian Res 2021;14:25.","DOI":"10.1186\/s13048-021-00780-6"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Hoyos LR, Putra M, Armstrong AA, et al. Measures of Patient Dissatisfaction With Health Care in Polycystic Ovary Syndrome: Retrospective Analysis. J Med Internet Res 2020;22:e16541.","DOI":"10.2196\/16541"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Ogden J, Bridge L. How communicating a diagnosis of polycystic ovarian syndrome (PCOS) impacts wellbeing: a retrospect i ve community survey. BJGP Open 2022;6:BJGPO.2022.0014.","DOI":"10.3399\/bjgpo.2022.0014"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011;26:3123-9.","DOI":"10.1093\/humrep\/der297"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-M\u00fcllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab 2010;95:4399-405.","DOI":"10.1210\/jc.2010-0334"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kiconco S, Teede HJ, Azziz R, et al. The Need to Reassess the Diagnosis of Polycystic Ovary Syndrome (PCOS): A Review of Diagnostic Recommendations from the International Evidence-Based Guideline for the Assessment and Management of PCOS. Semin Reprod Med 2021; 39:71-7.","DOI":"10.1055\/s-0041-1735259"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Cook H, Brennan K, Azziz R. Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism? Fertil Steril 2011;96:1266- 70.e1.","DOI":"10.1016\/j.fertnstert.2011.08.022"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Dokras A, Saini S, Gibson-Helm M, et al. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril 2017;107:1380-6.e1.","DOI":"10.1016\/j.fertnstert.2017.04.011"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Gibson-Helm M, Teede H, Dunaif A, et al. Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2017;102:604-12.","DOI":"10.1210\/jc.2016-2963"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Skiba MA, Islam RM, Bell RJ, et al. Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2018;24:694-709.","DOI":"10.1093\/humupd\/dmy022"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Kiconco S, Mousa A, Azziz R, et al. PCOS Phenotype in Unselected Populations Study (P-PUP): Protocol for a Systematic Review and Defining PCOS Diagnostic Features with Pooled Individual Participant Data. Diagnostics (Basel) 2021;11:1953.","DOI":"10.3390\/diagnostics11111953"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Zhu R, Lee BH, Huang Z, et al. Antim\u00fcllerian hormone, antral follicle count and ovarian volume predict menstrual cycle length in healthy women. Clin Endocrinol (Oxf) 2016;84:870-7.","DOI":"10.1111\/cen.12984"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Bull JR, Rowland SP, Scherwitzl EB, et al. Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. NPJ Digit Med 2019;2:83.","DOI":"10.1038\/s41746-019-0152-7"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Lim AJR, Indran IR, Kramer MS, et al. Phenotypic spectrum of polycystic ovary syndrome and their relationship to the circadian biomarkers, melatonin and cortisol. Endocrinol Diabetes Metab 2019;2:e00047.","DOI":"10.1002\/edm2.47"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Wang ET, Kao CN, Shinkai K, et al. Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study. Fertil Steril 2013; 100:214-8.","DOI":"10.1016\/j.fertnstert.2013.03.010"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Zhu RY, Wong YC, Yong EL. Sonographic evaluation of polycystic ovaries. Best Pract Res Clin Obstet Gynaecol 2016;37:25-37.","DOI":"10.1016\/j.bpobgyn.2016.02.005"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"di Clemente N, Racine C, Pierre A, et al. Anti-M\u00fcllerian Hormone in Female Reproduction. Endocr Rev 2021; 42:753-82.","DOI":"10.1210\/endrev\/bnab012"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Dewailly D, Barbotin AL, Dumont A, et al. Role of Anti- M\u00fcllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne) 2020;11:641.","DOI":"10.3389\/fendo.2020.00641"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Pigny P, Jonard S, Robert Y, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941-5.","DOI":"10.1097\/01.ogx.0000228703.76242.41"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012;27:2494-502.","DOI":"10.1093\/humrep\/des213"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Teede H, Misso M, Tassone EC, et al. Anti-M\u00fcllerian Hormone in PCOS: A Review Informing International Guidelines. Trends Endocrinol Metab 2019;30:467-78.","DOI":"10.1016\/j.tem.2019.04.006"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 2014;29:791-801.","DOI":"10.1093\/humrep\/det469"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Aydogan Mathyk B, Cetin E, Yildiz BO. Use of anti-M\u00fcllerian hormone for understanding ovulatory dysfunction in polycystic ovarian syndrome. Curr Opin Endocrinol Diabetes Obes 2022;29:528-34.","DOI":"10.1097\/med.0000000000000772"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Yildiz BO, Bolour S, Woods K, et al. Visually scoring hirsutism. Hum Reprod Update 2010;16:51-64.","DOI":"10.1093\/humupd\/dmp024"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Huang Z, Yong EL. Ethnic differences: Is there an Asian phenotype for polycystic ovarian syndrome? Best Pract Res Clin Obstet Gynaecol 2016;37:46-55.","DOI":"10.1016\/j.bpobgyn.2016.04.001"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016;31:2841-55.","DOI":"10.1093\/humrep\/dew218"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society [published correction appears in Hum Reprod Update 2013;19:207]. Hum Reprod Update 2012;18:146-70.","DOI":"10.1093\/humupd\/dms057"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Zhao X, Ni R, Li L, et al. Defining hirsutism in Chinese women: a cross-sectional study. Fertil Steril 2011;96:792-6.","DOI":"10.1016\/j.fertnstert.2011.06.040"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Pigny P, Gorisse E, Ghulam A, et al. Comparative assessment of five serum antim\u00fcllerian hormone assays for the diagnosis of polycystic ovary syndrome. Fertil Steril 2016;105:1063-9.e3.","DOI":"10.1016\/j.fertnstert.2015.12.023"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Pastuszek E, Lukaszuk A, Kunicki M, et al. New AMH assay allows rapid point of care measurements of ovarian reserve. Gynecol Endocrinol 2017;33:638-43.","DOI":"10.1080\/09513590.2017.1306735"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Hagen CP, Aksglaede L, S\u00f8rensen K, et al. Individual serum levels of anti-M\u00fcllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod 2012;27:861-6.","DOI":"10.1093\/humrep\/der435"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"La Marca A, Grisendi V, Griesinger G. How Much Does AMH Really Vary in Normal Women? Int J Endocrinol 2013; 2013:959487.","DOI":"10.1155\/2013\/959487"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Copp T, Hersch J, Muscat DM, et al. The benefits and harms of receiving a polycystic ovary syndrome diagnosis: a qualitative study of women\u2019s experiences. Hum Reprod Open 2019;2019:hoz026.","DOI":"10.1093\/hropen\/hoz026"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges, and Guiding Treatment. J Clin Endocrinol Metab 2021;106:e1071-e1083.","DOI":"10.1210\/clinem\/dgaa839"}],"container-title":["Annals of the Academy of Medicine, Singapore"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T08:03:47Z","timestamp":1703750627000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals.edu.sg\/polycystic-ovary-syndrome-v-2023-simplified-diagnostic-criteria-for-an-east-asian-phenotype\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,28]]},"published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.47102\/annals-acadmedsg.202369","relation":{},"ISSN":["0304-4602"],"issn-type":[{"value":"0304-4602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}